KOD vs REGN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. KOD and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined KOD and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Kodiak Sciences is a Palo Alto based biotechnology company developing therapies for high-prevalence retinal diseases such as diabetic retinopathy, wet age-related macular degeneration (wet AMD), and macular edema. Its programs are built on an antibody biopolymer conjugate (ABC) platform intended to extend how long a single injection lasts in the eye. The lead candidate, tarcocimab tedromer (branded Zenkuda), delivered positive Phase 3 GLOW2 data in diabetic retinopathy in early 2026, while additional Phase 3 studies (DAYBREAK in wet AMD with KSI-501, and PEAK and PINNACLE for KSI-101 in macular edema secondary to inflammation) are reading out into 2027.

Full KOD guide

Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base.

Full REGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• KOD drivers: Multi-indication Phase 3 pipeline; Durability-focused ABC platform.
• REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a pre-revenue clinical-stage biotech, Kodiak is exposed to binary trial risk, and a single failed Phase 3 readout can move the stock sharply, as the 2021 wet AMD failure demonstrated. For REGN, the clearest risk is Eylea biosimilar erosion.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick KOD if you believe its drivers more; REGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the KOD and REGN guides.

KOD. Kodiak has no product revenue and posts steady net losses, so traditional earnings multiples do not apply and valuation reflects pipeline expectations. Cash of roughly $170 million against a quarterly burn near $58 million supports operations into 2027, meaning further financing could be needed. The market capitalization near $1.3 billion effectively prices in the probability-weighted value of its Phase 3 programs.

REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron reported about 19% revenue growth and adjusted EPS of roughly $9.47 in Q1 2026, beating estimates, and authorized an additional $3 billion buyback. The mid-teens P/E reflects the market weighing strong Dupixent growth against expected Eylea biosimilar erosion.

Headline figures (approximate, JULY 2026): KOD shows revenue (ttm) ~$0 (no approved products), net loss (q1 2026) ~$58M, r&d expense (q1 2026) ~$49M, cash & equivalents (mar 2026) ~$170M; REGN shows total revenue (ttm, approx) ~$14 billion, q1 2026 total revenue ~$3.6 billion (up ~19% YoY), dupixent global net sales (q1 2026) ~$4.9 billion (up ~31%), eylea + eylea hd u.s. net sales (q1 2026) ~$941 million combined.

KOD and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined KOD and REGN exposure against your real portfolio. It is not an investment adviser.